Healthcare / Medical Instruments & SuppliesShanghai
$71.95
+0.18 (+0.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-36.0M · quality 27.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.3B
P/E
66.6x
↑EV/EBITDA
44.8x
↑ROE
3.0%
↑Gross Margin
63.7%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.2%
FCF CAGR
—
FCF margin
-10.5%
FCF / Net income
-0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $342.0M · net income $51.9M · FCF $-36.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $342.0M | $342.0M | $336.4M | $360.7M | $262.3M |
| Net Income | $51.9M | $51.9M | $98.7M | $117.3M | $75.4M |
| EBITDA | $66.0M | $66.0M | $125.3M | $137.8M | $83.8M |
| EPS | 1.15 | 1.15 | 1.97 | 2.53 | 1.90 |
| Gross Margin | 63.7% | 63.7% | 70.4% | 69.0% | 68.6% |
| Operating Margin | 11.8% | 11.8% | 22.4% | 30.3% | 26.7% |
| Net Margin | 15.2% | 15.2% | 29.3% | 32.5% | 28.7% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.00 | 0.00 | 0.02 |
| Current Ratio | 10.59 | 10.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-36.0M | $-36.0M | $-118.1M | $-35.6M | $29.9M |
| Returns | |||||
| ROE | 3.0% | 3.0% | 5.6% | 5.4% | 18.5% |
| Valuation | |||||
| P/E | 66.62 | 66.62 | 29.64 | 36.62 | — |
| EV/EBITDA | 44.82 | 44.82 | 18.88 | 26.05 | — |
| P/B | 1.88 | 1.88 | 1.66 | 1.99 | — |
| Growth & Yield | |||||
| Revenue Growth | 1.7% | 1.7% | -6.7% | 37.5% | — |
| EPS Growth | -41.6% | -41.6% | -22.1% | 33.2% | — |
| Dividend Yield | 1.4% | 1.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
77.1%
EPS terminal req.
$6.38
Spread vs growth
-118.7%
5Y implied EPS CAGR
46.4%
EPS terminal req.
$7.73
Spread vs growth
-88.0%
10Y implied EPS CAGR
26.9%
EPS terminal req.
$12.44
Spread vs growth
-68.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.7%
Start / end P/E
32.5x → 62.6x
EPS bridge
1.97 → 1.15
Residual
-38.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.